Viking Global Investors
TRVI icon

Viking Global Investors’s Trevi Therapeutics TRVI Stock Holding History

Viking Global Investors’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$38.2M Hold
3,198,644
– – 0.11% 72
2025
Q4 		$40M Sell
3,198,644
-1,930,231
-38% -$22.3M 0.11% 73
2025
Q3 		$46.9M Buy
5,128,875
+3,585,875
+232% +$26.9M 0.12% 73
2025
Q2 		$8.44M Sell
1,543,000
-1,684,792
-52% -$10.5M 0.02% 81
2025
Q1 		$20.3M Sell
3,227,792
-1,172,208
-27% -$5.59M 0.06% 84
2024
Q4 		$18.1M Hold
4,400,000
– – 0.06% 83
2024
Q3 		$14.7M Hold
4,400,000
– – 0.05% 80
2024
Q2 		$13.1M Hold
4,400,000
– – 0.05% 81
2024
Q1 		$15.2M Hold
4,400,000
– – 0.06% 80
2023
Q4 		$5.9M Hold
4,400,000
– – 0.02% 78
2023
Q3 		$9.59M Hold
4,400,000
– – 0.04% 76
2023
Q2 		$10.5M Hold
4,400,000
– – 0.04% 83
2023
Q1 		$8.14M Hold
4,400,000
– – 0.04% 77
2022
Q4 		$8.49M Hold
4,400,000
– – 0.04% 73
2022
Q3 		$6.78M Buy
+4,400,000
New +$14.4M 0.03% 88

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Viking Global Investors's TRVI Position: Q1 2026 in Review

Viking Global Investors held its Trevi Therapeutics (TRVI) position steady in Q1 2026 at 3,198,644 shares worth $38.2M. The position accounts for 0.11% of the portfolio, ranked #72.

Viking Global Investors first reported a position in TRVI in Q3 2022 and has held it in 15 quarters since. The position peaked at $46.9M in Q3 2025. 198 funds tracked by Wall St. Rank hold TRVI as of Q1 2026.

  • Viking Global Investors held 3,198,644 shares of Trevi Therapeutics worth $38.2M as of Q1 2026.
  • Viking Global Investors left its Trevi Therapeutics share count unchanged in Q1 2026.
  • Trevi Therapeutics made up 0.11% of Viking Global Investors's portfolio in Q1 2026, its #72 holding.
  • Viking Global Investors first reported a position in Trevi Therapeutics in Q3 2022 and has held it in 15 quarters since.
  • Viking Global Investors's Trevi Therapeutics position peaked at $46.9M in Q3 2025.
  • 198 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q1 2026.

Based on Viking Global Investors's 13F filing for Q1 2026, filed 15 May 2026.